Literature DB >> 20638391

Optimal control for resistance and suboptimal response in CML.

Bedr'Eddine Aïnseba1, Chahrazed Benosman.   

Abstract

The mathematical modelling of hematopoiesis received a significant attention in the last few years. However, the treatment of hematological diseases is less investigated by optimal control tools. In this paper, we consider the dynamics of chronic myeloid leukemia based on a four dimensional model. First we analyze the global dynamics of normal and cancer hematopoietic stem cells and differentiated cells using the principle of Bendixson-Dulac. Then we introduce some nonlinear effects of imatinib treatment over a fixed period of time. We represent therapy effects as an optimal control problem to minimize the cost of treatment and the level of cancer cells. The influence of imatinib onto the division and the mortality rates of cancer cells produces the suboptimal response, resistance and recovery forms. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638391     DOI: 10.1016/j.mbs.2010.06.005

Source DB:  PubMed          Journal:  Math Biosci        ISSN: 0025-5564            Impact factor:   2.144


  7 in total

1.  Evaluating optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy.

Authors:  Syndi Barish; Michael F Ochs; Eduardo D Sontag; Jana L Gevertz
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

2.  A multicellular basis for the origination of blast crisis in chronic myeloid leukemia.

Authors:  Rainer K Sachs; Kerstin Johnsson; Philip Hahnfeldt; Janet Luo; Allen Chen; Lynn Hlatky
Journal:  Cancer Res       Date:  2011-04-12       Impact factor: 12.701

Review 3.  The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer.

Authors:  Benjamin Wölfl; Hedy Te Rietmole; Monica Salvioli; Artem Kaznatcheev; Frank Thuijsman; Joel S Brown; Boudewijn Burgering; Kateřina Staňková
Journal:  Dyn Games Appl       Date:  2021-08-30       Impact factor: 1.296

4.  Evolutionary Dynamics of Chronic Myeloid Leukemia Progression: the Progression-Inhibitory Effect of Imatinib.

Authors:  Robert C Jackson; Tomas Radivoyevitch
Journal:  AAPS J       Date:  2016-03-23       Impact factor: 4.009

5.  Optimized Treatment Schedules for Chronic Myeloid Leukemia.

Authors:  Qie He; Junfeng Zhu; David Dingli; Jasmine Foo; Kevin Zox Leder
Journal:  PLoS Comput Biol       Date:  2016-10-20       Impact factor: 4.475

6.  The effects of time valuation in cancer optimal therapies: a study of chronic myeloid leukemia.

Authors:  Pedro José Gutiérrez-Diez; Miguel Ángel López-Marcos; Julia Martínez-Rodríguez; Jose Russo
Journal:  Theor Biol Med Model       Date:  2019-05-28       Impact factor: 2.432

7.  dNTP Supply Gene Expression Patterns after P53 Loss.

Authors:  Tomas Radivoyevitch; Yogen Saunthararajah; John Pink; Gina Ferris; Ian Lent; Mark Jackson; Damian Junk; Charles A Kunos
Journal:  Cancers (Basel)       Date:  2012-11-20       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.